Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 691.50
Bid: 691.00
Ask: 692.00
Change: -0.50 (-0.07%)
Spread: 1.00 (0.145%)
Open: 689.00
High: 694.50
Low: 689.00
Prev. Close: 692.00
TATE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

New Venture Fund

8 Nov 2012 07:01

null

Tate & Lyle to expand its global innovation programme through a new £30 million venture fund (Tate & Lyle Ventures II)

Tate & Lyle PLC announced today an investment of up to £30 million over an eight-year period in a new venture capital fund, building on Tate & Lyle's existing venture fund activities.

The new Fund will invest in start-ups and expansion-stage companies in both developed and emerging markets in food sciences and enabling technologies in line with Tate & Lyle's strategy to grow in speciality food ingredients.

The new Fund will be formally launched on 1 January 2013. As with Tate & Lyle's first venture fund, which was launched in April 2006, the new Fund will be independently led and managed by Simon Barnes and David Atkinson.

"This is an important investment in our global innovation programme and represents another step in building Tate & Lyle's platform for long-term growth" said Karl Kramer, President, Innovation and Commercial Development, Tate & Lyle.

Kramer added, "We have seen with our first Fund how beneficial a corporate venturing capability can be. The combination of the new Fund and our internal Open Innovation team will enable us to access the full spectrum of new ideas, technologies and opportunities in the global food science and investment community. This is an investment for long-term growth and, ultimately, will help us deliver more innovative solutions for our customers".

David Atkinson, Tate & Lyle Ventures said, "We are continuing to see a real change in consumer attitudes towards health and nutrition and in particular the growing interest in functional foods. Busy lives, an ageing population and rapid urbanization in emerging markets mean that consumers across the world are looking to food to offer lifestyle solutions and bring added benefits such as fortification and enrichment. New technologies will be instrumental in this convergence as the world's major food companies increasingly reposition themselves with a focus on innovation and health."

Simon Barnes, Tate & Lyle Ventures said, "We will be looking to invest in companies based on strong intellectual property and with strong management teams. As with the first Fund, the independent structure of the new Fund means we can leverage Tate & Lyle's core expertise in helping us to build our portfolio whilst retaining the ability to manage the investments in accordance with sound venture capital principles."

Notes to Editors:

1. For more details on the fund, please contact:

David Atkinson - david.atkinson@tateandlyleventures.com

Simon Barnes - simon.barnes@tateandlyleventures.com

2. The fund will have £30 million of committed capital at closing and is looking to back 8-10 deals over several rounds of finance. Optimal investment sizes are between £2-5 million.

3. Like the first Fund, Tate & Lyle Ventures II will be managed by Circadia Ventures LLP of which Simon Barnes and David Atkinson are the Managing Partners. Circadia Ventures LLP was founded in 2006 and is authorized and regulated by the Financial Services Authority. Simon and David's biographies are:

Simon Barnes

Simon Barnes has a background in life sciences venture capital, first with the London office of Atlas Venture and subsequently with GIMV Venture Capital. He has focused since 1998 on investing in university spin-outs. Simon was trained as a scientist and has a first class degree in Natural Sciences and a PhD from the University of Cambridge. Together with David Atkinson, Simon co-founded Circadia Ventures LLP in 2006. Simon currently sits on the boards of Allylix Inc., Aquapharm BioDiscovery Ltd., Fugeia NV and Lumora Ltd.

David Atkinson

David Atkinson has held a number of senior management positions in the City, with 14 years' experience in equity research focusing on the food processing industry, whilst he alsoco-founded Stamford Partners, the European food and drink industry advisory firm. Together with Simon Barnes, David co-founded Circadia Ventures LLP in 2006. David currently sits on the boards of BioFilm Holdings Ltd., Fugeia NV and Lumora Ltd.

Copyright Business Wire 2012

Date   Source Headline
28th Jul 20221:00 pmRNSUpdate on Preference Share Reduction Timetable
28th Jul 202212:45 pmRNSResult of AGM
15th Jul 20225:20 pmRNSDirector/PDMR Shareholding
1st Jul 202210:45 amRNSBlock listing Interim Review
1st Jul 202210:17 amRNSTotal Voting Rights
29th Jun 20224:25 pmRNSDirector/PDMR Shareholding
29th Jun 20224:00 pmRNSDirector/PDMR Shareholding
24th Jun 20224:15 pmRNSHolding(s) in Company
23rd Jun 20223:00 pmRNSHolding(s) in Company
21st Jun 20222:30 pmRNSAnnual Financial Report and Notice of Meeting 2022
17th Jun 20222:00 pmRNSHolding(s) in Company
15th Jun 20222:00 pmRNSHolding(s) in Company
15th Jun 20227:00 amRNSProposed Cancellation&Repayment Preference Shares
10th Jun 20222:00 pmRNSHolding(s) in Company
9th Jun 20227:06 amRNSAcquisition
9th Jun 20227:00 amRNSFinal Results
19th May 20225:00 pmRNSDirector/PDMR Shareholding
9th May 20222:23 pmRNSHolding(s) in Company
6th May 20222:46 pmRNSHolding(s) in Company
3rd May 20225:45 pmRNSHolding(s) in Company
3rd May 20228:01 amRNSShare Consolidation Effective Total Voting Rights
29th Apr 20223:15 pmRNSListing and Trading Application
26th Apr 20224:00 pmRNSResult of Meeting
13th Apr 20222:00 pmRNSHolding(s) in Company
7th Apr 20225:30 pmRNSHolding(s) in Company
7th Apr 202211:00 amRNSCirc re. special dividend and share consolidation
5th Apr 20224:00 pmRNSHolding(s) in Company
4th Apr 20224:00 pmRNSDirector/PDMR Shareholding
1st Apr 20222:15 pmRNSDisposal completion
1st Apr 20222:00 pmRNSTotal Voting Rights
31st Mar 20227:00 amRNSAcquisition
24th Mar 20222:00 pmRNSHolding(s) in Company
24th Mar 202211:00 amRNSDirectorate Change
21st Mar 20222:00 pmRNSHolding(s) in Company
18th Mar 20223:30 pmRNSHolding(s) in Company
10th Mar 20222:00 pmRNSHolding(s) in Company
9th Mar 20222:00 pmRNSHolding(s) in Company
1st Mar 20229:22 amRNSTotal Voting Rights
18th Feb 20222:00 pmRNSHolding(s) in Company
17th Feb 20222:00 pmRNSHolding(s) in Company
14th Feb 20222:00 pmRNSHolding(s) in Company
11th Feb 20227:00 amRNSTrading Statement
10th Feb 20222:00 pmRNSHolding(s) in Company
9th Feb 20227:00 amRNSDirectorate Change
3rd Feb 20224:00 pmRNSHolding(s) in Company
1st Feb 20223:30 pmRNSHolding(s) in Company
21st Jan 20222:00 pmRNSHolding(s) in Company
17th Jan 20222:00 pmRNSHolding(s) in Company
12th Jan 20224:00 pmRNSHolding(s) in Company
10th Jan 20223:45 pmRNSChange of Registered Office

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.